These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 33331740)
1. Is there a paradigm shift in preventing diabetic heart failure? A review of SGLT2 inhibitors. Khakde S; Jawaid H; Yasmin F; Binte Ali M; Rehman A Minerva Endocrinol (Torino); 2022 Sep; 47(3):344-357. PubMed ID: 33331740 [TBL] [Abstract][Full Text] [Related]
2. Class effects of SGLT2 inhibitors on cardiorenal outcomes. Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965 [TBL] [Abstract][Full Text] [Related]
5. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease. Mima A J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432 [TBL] [Abstract][Full Text] [Related]
6. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction. Liu B; Wang Y; Zhang Y; Yan B Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521 [TBL] [Abstract][Full Text] [Related]
7. [Cardiorenal protection with SGLT2 inhibitors (gliflozins) : from EMPA-REG OUTCOME to CANVAS]. Scheen AJ; Ernest P; Jandrain B Rev Med Suisse; 2017 Aug; 13(571):1421-1426. PubMed ID: 28837279 [TBL] [Abstract][Full Text] [Related]
8. Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes. Trujillo JM; Nuffer WA Pharmacotherapy; 2017 Apr; 37(4):481-491. PubMed ID: 28102030 [TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. Scheen AJ Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368 [TBL] [Abstract][Full Text] [Related]
10. Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review. Kluger AY; Tecson KM; Barbin CM; Lee AY; Lerma EV; Rosol ZP; Rangaswami J; Lepor NE; Cobble ME; McCullough PA Rev Cardiovasc Med; 2018 Jun; 19(2):41-49. PubMed ID: 31032602 [TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Garcia-Ropero A; Badimon JJ; Santos-Gallego CG Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454 [TBL] [Abstract][Full Text] [Related]
13. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association. Lee S Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644 [TBL] [Abstract][Full Text] [Related]
14. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients. Nakagawa Y; Kuwahara K J Cardiol; 2020 Aug; 76(2):123-131. PubMed ID: 32340780 [TBL] [Abstract][Full Text] [Related]
15. SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models. Andreadou I; Bell RM; Bøtker HE; Zuurbier CJ Biochim Biophys Acta Mol Basis Dis; 2020 Jul; 1866(7):165770. PubMed ID: 32194159 [TBL] [Abstract][Full Text] [Related]
16. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science. Cruz JE; Ahuja T; Bridgeman MB Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393 [TBL] [Abstract][Full Text] [Related]
17. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Xu B; Li S; Kang B; Zhou J Cardiovasc Diabetol; 2022 May; 21(1):83. PubMed ID: 35614469 [TBL] [Abstract][Full Text] [Related]
18. SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome. van Bommel EJM; Muskiet MHA; Tonneijck L; Kramer MHH; Nieuwdorp M; van Raalte DH Clin J Am Soc Nephrol; 2017 Apr; 12(4):700-710. PubMed ID: 28254770 [TBL] [Abstract][Full Text] [Related]
19. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population. Wittbrodt ET; Eudicone JM; Bell KF; Enhoffer DM; Latham K; Green JB Am J Manag Care; 2018 Apr; 24(8 Suppl):S138-S145. PubMed ID: 29693360 [TBL] [Abstract][Full Text] [Related]
20. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]